The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
As long as Tata Sons cannot deregister itself as NBFC, the listing criteria of RBIs NBFCs in the Upper Layer (NBFC-UL) rule will hang on the company. If it does manage to deregister, then it can avoid ...
Aardvark said it applied to list on the Nasdaq Global Market under the symbol AARD. The company didn't give an expected size for its IPO, nor did it offer an expected price range. Morgan Stanley, B of ...